Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Modified vaccinia virus Ankara (MVA)-vectored vaccines against malaria, influenza, tuberculosis and recently Ebola virus are in clinical development. Although this vector is safe and immunogenic in humans, efforts remain on-going to enhance immunogenicity through various approaches such as using stronger promoters to boost transgene expression. We previously reported that endogenous MVA promoters such as pB8 and pF11 increased transgene expression and immunogenicity, as compared to the conventional p7.5 promoter. Here, we show that both promoters also rivalled the mH5 promoter in enhancing MVA immunogenicity. We investigated the mechanisms behind this improved immunogenicity and show that it was a result of strong early transgene expression in vivo, rather than in vitro as would normally be assessed. Moreover, keeping the TK gene intact resulted in a modest improvement in immunogenicity. Utilizing pB8 or pF11 as ectopic promoters at the TK locus instead of their natural loci also increased transgene expression and immunogenicity. In addition to a reporter antigen, the pF11 promoter was tested with the expression of two vaccine antigens for which cellular immunogenicity was significantly increased as compared to the p7.5 promoter. Our data support the use of the pF11 and pB8 promoters for improved immunogenicity in future MVA-vectored candidate vaccines.

Original publication

DOI

10.1016/j.vaccine.2015.11.028

Type

Journal article

Journal

Vaccine

Publication Date

02/01/2016

Volume

34

Pages

49 - 55

Keywords

Immunogenicity, MVA, Promoter, Transgene expression, Vaccine development, Viral vector, Animals, Drug Carriers, Enzyme-Linked Immunospot Assay, Female, Gene Expression, Genetic Vectors, Influenza Vaccines, Interferon-gamma, Leukocytes, Mononuclear, Malaria Vaccines, Mice, Inbred BALB C, Promoter Regions, Genetic, Transgenes, Treatment Outcome, Vaccines, Synthetic, Vaccinia virus